Status:
COMPLETED
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Leukemia
Eligibility:
All Genders
Up to 21 years
Brief Summary
RATIONALE: A screening test, such as My Profile Pediatric Assay, may help doctors predict a patient's risk of relapse and plan better treatment for acute myeloid leukemia. PURPOSE: This clinical tria...
Detailed Description
OBJECTIVES: Primary * To validate the accuracy of the My Profile Pediatric Assay to predict risk of relapse in pediatric patients with non-M3 acute myeloid leukemia (AML) who responded to cytarabine...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Patients with confirmed non-M3 acute myeloid leukemia
- Treated on COG-AAML03P1 or COG- AAML0531 protocols
- Samples from COG-AAML0531 can come from either treatment arm, but these samples need to be independent from any patients who donated samples assayed in study COG-AAML11B2
- Patients with Down syndrome are excluded
- Cryopreserved bone marrow mononuclear cell (BMMC) samples collected at diagnosis, prior to start induction therapy
- Samples must have been cryopreserved at central lab within 3 days of draw at clinical site
- Target of 10 X 10\^6 cells frozen
- Patients' clinical annotations required after unblinding
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2016
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT01438138
Start Date
September 1 2011
End Date
May 1 2016
Last Update
May 18 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.